News & Videos - BIOPORTO A/S [CBOE]

April 10, 2024 Announcement no. 8 BioPorto A/S Appoints Chief Legal Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 10, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the appointment of Gry Louise Husby Larsen as its new Executive Vice President and Chief Legal Officer (CLO), and member of the Executive Management team as of April 15, 2024....

April 5, 2024 Announcement no. 7 New Board Candidate for the upcoming Annual Geneal Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, April 5, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that the Company has received notice that Tonni Bülow-Nielsen, due to personal reasons, will not be a candidate for the upcoming general meeting on 30 April 2024....

April 4, 2024 Announcement no. 6 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: Tuesday April 30, 2024, at 3.00 p.m. (CEST) At the Company’s address Tuborg Havnevej 15, st., DK-2900 Hellerup, Denmark AGENDA: ITEM 1 - REPORT ON THE COMPANY’S ACTIVITIES DURING THE PAST YEAR The Board of Directors proposes that the Board's report on the Company’s...

Correction: Updated Annual Report attached April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today financial results for the year ended December 31, 2023. Highlights 2023 Revenue and adjusted EBITDA in 2023 are in line with the...

April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today financial results for the year ended December 31, 2023. Highlights 2023 Revenue and adjusted EBITDA in 2023 are in line with the preliminary results announced on February 22,...

April 2, 2024 Announcement no. 04 BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 2, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the appointment of Peter Mørch Eriksen as permanent Group CEO of BioPorto. Peter Mørch Eriksen was appointed as interim CEO of BioPorto...

February 22, 2024 Announcement no. 03 BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 COPENHAGEN, DENMARK and BOSTON, MA, February 22, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), today announced its preliminary results for 2023 and described its strategy and expectations for 2024-2026 and beyond. Securing FDA clearance and meeting financial targets in 2023 In December 2023, BioPorto passed a major...

20 February 20, 2024 Announcement no. 02 Roche Diagnostics and BioPorto expand collaboration COPENHAGEN, DENMARK and BOSTON, MA, 20 February, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has today announced an expansion of its strategic collaboration with Roche Diagnostics. As announced on December 7, 2023, BioPorto received FDA clearance in the US for its NGAL test to be marketed as ProNephro AKI™ (NGAL) on Roche’s cobas® c 501. ProNephro AKI (NGAL) is...

January 9, 2024 Announcement no. 01 BioPorto implements changes to the Executive Management. COPENHAGEN, DENMARK and BOSTON, MA, January 9, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), today announced changes to the Executive Management. By mutual agreement, BioPorto’s CEO, Anthony Pare, is stepping down and leaving BioPorto with effect from today. Peter Mørch Eriksen has been appointed as interim CEO. Chairman John McDonough says: “We are excited to have...

December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial...

December 7, 2023 Announcement no. 20 BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years COPENHAGEN, DENMARK and BOSTON, MA, December 7, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), today announced receipt of a US Food and Drug Administration (FDA) 510(k) clearance for BioPorto’s NGAL test, to be marketed as ProNephro AKI TM (NGAL). ProNephro AKI (NGAL)...

December 4, 2023 Announcement no. 19 Resignation of Director COPENHAGEN, DENMARK and BOSTON, MA, USA, December 4, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) announced today that Jan Leth Christensen has informed the Company that he has decided to resign from his position as a board member for BioPorto. The search for a successor with relevant expertise, including familiarity with public company practices in the Nordics, will be initiated and a new...

November 1, 2023 Announcement no. 18 BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023 COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results and business updates for the third quarter and nine months of fiscal 2023. Recent Highlights For the first nine months ending September 30, 2023: Total revenue of DKK 24.4 million / USD 3.5...

October 31, 2023 Announcement no. 17 BioPorto provides interim Q3 results and revised 2023 Financial Guidance. COPENHAGEN, Denmark and BOSTON, MA, USA, October 31, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced a change in the Company’s 2023 financial guidance and interim results for the first nine months and third quarter of fiscal year 2023. Interim Results For the third quarter ending September 30, 2023: Total revenue of DKK 8.6 million / USD 1.3 million, a...

September 22 , 20 2 3 Announcement no. 1 6 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, September 22, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 700,000 warrants to members of the Board of Directors of the Company, and further to issue a total of 2,750,000 warrants to employees of the BioPorto...

September 19, 2023 Announcement no. 15 BioPorto Initiates Search for new CFO as Neil Goldman Resigns COPENHAGEN, DENMARK and BOSTON, MA, USA, September 19, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) announced today that Neil Goldman has informed the Company that he has decided to resign to take up the CFO position at another company. The search for a successor will be initiated and Neil Goldman will assist with the transition until a date to be...

August 1, 2023 Announcement no. 14 BioPorto Announces Interim Results for the First Six Months of 2023 COPENHAGEN, Denmark and BOSTON, MA, USA, August 1, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first six months of 2023 and business progress for the second quarter of 2023. Recent Highlights For the six months ending June 30, 2023: Total revenue of DKK 15.8 million / USD 2.3 million, a 5% increase over the prior year Adjusted...

June 2 8 , 202 3 Announcement no. 13 Managers’ transactions In connection with the completion of BioPorto A/S’ rights issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them. 1. Details of the person discharging managerial...

June 23, 2023 Announcement no. 12 BioPorto A/S announces completion of rights issue; total number of shares and voting rights COPENHAGEN, Denmark and BOSTON, MA, USA, June 23, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (“BioPorto” or the “Company”) today announces the completion of the rights issue launched on May 30, 2023 (“the Offering”), raising gross proceeds of approximately DKK 43 million and estimated net proceeds of DKK 41.4 million. The 42,977,456 new shares will be admitted to...

June 21, 2023 Announcement no. 11 BioPorto A/S announces results of rights issue COPENHAGEN, Denmark and BOSTON, MA, USA, June 21, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (“BioPorto” or the “Company”) today announces that the rights issue launched on May 30, 2023 (the “Offering”), will raise gross proceeds of approximately DKK 43 million upon receipt of payment for the subscribed shares later this week. “We are pleased to announce the Offering’s results. The proceeds from the...